A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2748 in Hepatitis C-Infected Participants
Phase of Trial: Phase I
Latest Information Update: 06 Mar 2013
At a glance
- Drugs MK 2748 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- 01 Feb 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 Nov 2012 Planned number of patients changed from 36 to 60 as reported by ClinicalTrials.gov.
- 06 Nov 2012 Planned End Date changed from 1 Jun 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.